RFK Jr. Emphasizes Lifestyle over Weight Loss Drugs

Robert F. Kennedy Jr., nominated by President Donald Trump to lead the Department of Health and Human Services, shared his views on the growing weight loss drug sector on Thursday. Speaking with Jim Cramer from CNBC on the New York Stock Exchange, Kennedy emphasized the importance of healthy living as the primary approach to weight management.

Known for his critical perspective on the pharmaceutical industry, Kennedy stressed that the initial response to obesity should focus on lifestyle changes rather than immediately turning to GLP-1 drugs. His comments came during a period of close scrutiny by Wall Street regarding the potential effects of health policy following his nomination by Trump last month.

GLP-1 drugs, including Novo Nordisk's Wegovy and Ozempic as well as Eli Lilly's Zepbound and Mounjaro, have seen a significant increase in popularity, leading to a competitive race among pharmaceutical companies. The investor community remains particularly optimistic about Novo and Eli Lilly; Eli Lilly has become the world's most valuable health company. Predictions indicate that the market for these drugs could reach or exceed $100 billion by 2030.

As Kennedy awaits confirmation from the Senate, his stance on GLP-1 drugs has become a focal point for investors trying to forecast future health policies. Kennedy's presence on the New York Stock Exchange, along with other cabinet nominees, was part of a ceremonious opening bell event conducted under Trump’s leadership that marked the beginning of the trading session.